The action profile of lispro is not blunted by mixing in the syringe with NPH insulin

Diabetes Care

Volumn 21, Issue 12, 1998, Pages 2098-2102

  Joseph, Stonny E ^c   Korzon Burakowska, Anna ^a   Woodworth, James R ^b   Evans, Mark ^c   Hopkins, David ^c   Janes, Jonathan M ^d   Amiel, Stephanie A ^c  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b ELI LILLY AND COMPANY   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d Eli Lilly   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN LISPRO; ISOPHANE INSULIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; DRUG ABSORPTION; DRUG MIXTURE; DRUG SCREENING; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HUMAN; INSULIN BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; STATISTICAL ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION; SYRINGE;

EID: 0031765721     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.12.2098     Document Type: Article

References (21)

1. DiMarchi RD, Mayer JP, Fan L, Brems DN, Frank BH, Green LK, Huffman JA, Howey DC, Long HB, Shaw WN, Shields JE, Slicker LJ, Su KSE, Sundell KL, Chance RE: Synthesis of a fast-acting insulin based on structural homology with insulin-like growth factor 1. In Peptides: Chemistry and Biology, Proceedings of the Twelfth American Symposium. Smith JA, River JE, Eds. Leiden, the Netherlands. ESCOM, 1992, p. 26-28
2. Howey DC, Bowsher RR, Brunnelle RL, Woodworth JR: [Lys(B28), Pro(B29)]- human insulin: a rapidly absorbed analogue of human insulin. Diabetes 43:396-402, 1994
3. Kang S, Brange J, Burch A, Volund A, Owens D: Subcutaneous insulin absorption explained by insulin's physiochemical properties: evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care 14:942-948, 1991
4. Radzuik JM, Davies JC, Pye WS, Shields JE, DiMarchi RD, Chance RE: Bioavailability and bioeffectiveness of subcutaneous human insulin and two of its analog: LysB28ProB29- human insulin and AspB10LysB28ProB29- human insulin assessed in a conscious pig model Diabetes 46:548-556, 1997
5. Howey DC, Bowsher RR, Brunelle RL, Rowe HM, Santa PF, Downing-Shelton JM, Woodworth JR: [Lys(B28), Pro(B29)] human insulin: effect of injection time of post-prandial glycemia. Clin Pharmacol Ther 58:459-469, 1995
6. Pampenelli S, Torlone E, Ialli C, Del Sindaco P, Ciofetta M, Lepore M, Bartocci L, Brunetti P, Bolli GB: Improved post-prandial metabolic control after subcutaneous injection of a short acting insulin analog in IDDM of short duration with residual beta cell function. Diabetes Care 18:945-952, 1995
7. Heinemann L, Hiese T, Wahl LC, Trautmann ME, Ampudia J, Starke AA, Berger M: Prandial glycemia after a carbohydrate rich meal in type 1 diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med 13:625-629, 1996
8. Ebeling P, Jansson P-A, Smith U, Lalli C, Bolli GB, Koivisto VA: Strategies toward improved control during insulin lispro therapy in IDDM: importance of basal insulin. Diabetes Care 20:1287-1289, 1997
9. Krayenbuhl CH, Rosenberg TH: Crystalline protamine insulin. Rep Steno Hasp (Kbh) 1:60-73, 1946
10. Liu D, Moberg E, Kollind K, Lins P-E, Macdonald IA: Arterial, arterialized venous, venous and capillary blood glucose measurements in normal man during hyperin-sulinaemic euglycaemia and hypoglycaemia, Diabetologia 35:287-290, 1992
11. Kumar A, Chapoteau E, Czech B, Gebauer C, Chimenti M, Raimondo O: Chromogenic ionophore-based methods for spectrometric assay of sodium and potassium in serum and plasma. Clin Chem 34:1709-1712, 1988
12. Sapin R: Anti-insulin antibodies in insulin immunometric assay: a still possible pitfall. Eur J Clin Chem Clin Biochem 35:365-367, 1997
13. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-223, 1979
14. Lean MEJ, Ng LL, Tennison BR: Interval between insulin injection and eating in relation to blood glucose in adult diabetics. Br Med J 290:105-108, 1985
15. Dimitradis G, Gerich J: Importance of timing of pre-prandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 8:374-377, 1985
16. Heine RJ, Bilo HJG, Fonk T, van der Veen EA, van der Meer J: Absorption kinetics and action profiles of mixtures of short and intermediate acting insulins. Diabetologia 27:558-562, 1984
17. Torlone E, Pampanelli S, Lalli C, Del Sindaco P, Di Vicenzo A, Rambotti AM, Modarelli F, Epifano L, Kassi G, Perriello G, Brunetti P, Bolli G: Effects of the short acting insulin analog [Lys(B28),Pro(B29)] on post- prandial blood glucose control in IDDM. Diabetes Care 19:945-952, 1996
18. Jacobs MA, Keulen ET, Kanc K, Casteleijn S, Scheffer P, Deville W, Heine RJ: Metabolic efficacy of preprandial administration of Lys(B28),Pro(B29) human insulin analog in IDDM patients: a comparison with human regular insulin during a three-meal test period. Diabetes Care 20:1279-1286, 1997
19. Heise T, Weyer C, Serwas A, Heinrichs S, Osinga J, Roach P, Woodwonh J, Gudat U, Heinemann L: Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 21:800-803, 1998
20. Tuominen JA, Karonen SL, Melamies L, Bolli GB, Koivisto VA: Exercise induced hypoglycemia in IDDM patients treated with a short acting insulin analogue. Diabetologia 38:106-111, 1995
21. Heller S, Amiel SA, Janes J: Hypoglycemia during intensified insulin therapy: a comparison of lispro and regular insulin (Abstract). Diabetes 46 (Suppl. 1):151A, 1997